Patients receiving Adakveo should be monitored for signs and symptoms of infusion-related reactions.
That dose was shown to lower the frequency of annual VOCs in SCD patients in the company’s Phase 2 SUSTAIN (NCT01895361) trial. Reductions in … Findings from SUSTAIN demonstrated that Adakveo significantly reduced the frequency of annual VOCs by 45% compared to placebo (1.63 versus 2.98) at the 5 mg/kg dose.
Monitor patients for signs and … Crizanlizumab-tmca (Adakveo ... (SUSTAIN trial; NCT01895361). The result of the Phase II SUSTAIN clinical trial was published in December 2016.
The efficacy of crizanlizumab was evaluated in patients with sickle cell disease in SUSTAIN (NCT01895361), a 52week, randomized, multicenter, placebo-controlled, double-blind trial. In the SUSTAIN clinical trial, infusion-related reactions (defined as occurring within 24 hours of infusion) were observed in 2 (3%) patients treated with ADAKVEO 5 mg/kg. ADAKVEO reduced the number of pain crises people had regardless of sickle cell disease genotype and whether or not they were taking hydroxyurea.
Crizanlizumab, (brand name Adakveo), is a monoclonal antibody developed by Novartis targeted towards P-selectin. The FDA approved ADAKVEO based on evidence from one clinical trial (Trial 1/NCT01895361) of 132 patients with SS diseases who had a history of VOC. Adakveo was approved based on results from the yearlong Phase 2 SUSTAIN trial (NCT01895361) in 198 SCD patients with a history of frequent vaso-occlusive crises. Adakveo, a man-made antibody, works to block … 67 people taking ADAKVEO experienced a median annual rate of 4.0 days in the hospital vs 6.87 days for 65 people taking placebo—a 42% reduction. Monitor patients for signs and …
Cautions for Adakveo Contraindications. In the SUSTAIN clinical trial, infusion-related reactions (defined as occurring within 24 hours of infusion) were observed in 2 (3%) patients treated with ADAKVEO 5 mg/kg. Warnings/Precautions Infusion-related Reactions.
Monitor patients for signs and … In the SUSTAIN clinical trial, infusion-related reactions (defined as occurring within 24 hours of infusion) were observed in 2 (3%) patients treated with ADAKVEO 5 mg/kg. 1. Data showed treatment, given each month by intravenous infusion at a 5 mg/kg dose, lowered the annual rate of these pain crises by 45% compared to placebo, and the number of days spent in a hospital each year. The FDA’s decision to approve Adakveo 5 mg/kg is based on results of the 52-week, randomized, placebo-controlled SUSTAIN trial, which showed that Adakveo significantly lowered the median annual rate of VOCs to 1.63 vs 2.98 compared to placebo (P=.010), which is equivalent to a 45% reduction. In the SUSTAIN clinical trial, infusion-related reactions (defined as occurring within 24 hours of infusion) were observed in 2 (3%) patients treated with ADAKVEO 5 mg/kg. Adakveo is administered via intravenous infusion over a period of 30 minutes on Week 0, Week 2, and every 4 weeks thereafter.
Monitor patients for signs and symptoms of infusion-related reactions, which may include fever, chills, nausea, vomiting, fatigue, dizziness, pruritus, urticaria, sweating, shortness of breath or wheezing.